Oral Viscous Budesonide for Children with Eosinophilic Esophagitis

A reduction in esophageal eosinophilia improved symptomatic, endoscopic, and histologic disease parameters.

Although eosinophilic esophagitis (EoE) is increasingly recognized in both children and adults, an optimal treatment strategy has yet to be defined (JW Gastroenterol Sep 3 2010). The preferred approach has been to use a topical steroid, such as fluticasone propionate (a corticosteroid), administered with an aerosolized metered-dose inhaler; systemic steroids are also effective, but these agents are rarely needed. Oral viscous budesonide (OVB) suspension has also been shown to significantly improve EoE symptoms as well as endoscopic and histologic features in children.

To further assess OVB in this setting, investigators conducted a double-blind, randomized, placebo-controlled study involving 24 children (age range, 3–16 years; mean age, 7.8)…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors